A major trial to see if a common bone-building drug could help prevent the recurrence of breast cancer found do not receive the majority of patients, doctors, said Thursday.
Five years, called the trial study AZURE, followed 3,360 women with advanced breast cancer who had undergone surgery.
Some take the drug Zometa, also called the zoledronic acid, in addition to standard therapy randomly osteoporosis study. Zometa is made by the Switzerland pharmaceutical giant Novartis.
The hope was prevents cancer resurfacing, as it often does in the bones of the survivor.
But the American Association for cancer research has found that the drug have no impact on "" for the group as a whole"disease-free survival.
"Overall population, we did not see a difference", said Robert Coleman, Professor of medical oncology at the University of Sheffield, England, who presented the results of a Conference in San Antonio, Texas.
He added, however, there was a slight difference between age groups, with elderly patients a little more exiting on the drug.
30% Of the group who were postmenopausal at least five years, 1,101 overall, has seen an improvement of 29 per cent overall survival, which was "not likely to be a chance to find" said Coleman.
"We clearly want investigate later in this population."
He added, however, that "young patients receive no benefit." If they do worse. »
Zoledronic acid is a bisphosphonate that works by reducing the amount of calcium released by bones in the blood.
It is used to treat blood calcium levels that may coincide with cancer and to prevent fractures in patients with cancer.
No comments:
Post a Comment